BofA lowered the firm’s price target on Tempus AI (TEM) to $48 from $60 and keeps a Neutral rating on the shares. Sentiment for Life Sciences ...

Tempus AI (TEM) announced the company is scheduled to exhibit 4 abstracts at the American College of Cardiology, ACC, Annual Meeting, which convenes from March 29-31 in Chicago, Illinois.